• Je něco špatně v tomto záznamu ?

Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients

V. Vymetalkova, F. Rosa, S. Susova, P. Bendova, M. Levy, T. Buchler, J. Kral, L. Bartu, L. Vodickova, DJ. Hughes, P. Soucek, A. Naccarati, R. Kumar, P. Vodicka, B. Pardini

. 2020 ; 35 (3) : 273-281. [pub] 20200711

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012369

The chemotherapeutic efficacy in colorectal cancer (CRC) is limited due to the inter-individual variability in drug response and the development of tumour resistance. ATP-binding cassette (ABC) transporters are crucial in the development of resistance by the efflux of anticancer agents from cancer cells. In this study, we identified 14 single nucleotide polymorphisms (SNPs) in 11 ABC transporter genes acting as an expression of quantitative trait loci (eQTLs), i.e. whose variation influence the expression of many downstream genes. These SNPs were genotyped in a case-control study comprising 1098 cases and 1442 healthy controls and analysed in relation to CRC development risk and patient survival. Considering a strict correction for multiple tests, we did not observe any significant association between SNPs and CRC risk. The rs3819720 polymorphism in the ABCB3/TAP2 gene was statistically significantly associated with shorter overall survival (OS) in the codominant, and dominant models [GA vs. GG, hazard ratio (HR) = 1.48; P = 0.002; AA vs. GG, HR = 1.70; P = 0.004 and GA + AA vs. GG, HR = 1.52; P = 0.0006]. Additionally, GA carriers of the same SNP displayed worse OS after receiving 5-FU based chemotherapy. The variant allele of rs3819720 polymorphism statistically significantly affected the expression of 36 downstream genes. Screening for eQTL polymorphisms in relevant genes such as ABC transporters that can regulate the expression of several other genes may help to identify the genetic background involved in the individual response to the treatment of CRC patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012369
003      
CZ-PrNML
005      
20210507103738.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/mutage/gez050 $2 doi
035    __
$a (PubMed)31922572
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vymetalkova, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients / $c V. Vymetalkova, F. Rosa, S. Susova, P. Bendova, M. Levy, T. Buchler, J. Kral, L. Bartu, L. Vodickova, DJ. Hughes, P. Soucek, A. Naccarati, R. Kumar, P. Vodicka, B. Pardini
520    9_
$a The chemotherapeutic efficacy in colorectal cancer (CRC) is limited due to the inter-individual variability in drug response and the development of tumour resistance. ATP-binding cassette (ABC) transporters are crucial in the development of resistance by the efflux of anticancer agents from cancer cells. In this study, we identified 14 single nucleotide polymorphisms (SNPs) in 11 ABC transporter genes acting as an expression of quantitative trait loci (eQTLs), i.e. whose variation influence the expression of many downstream genes. These SNPs were genotyped in a case-control study comprising 1098 cases and 1442 healthy controls and analysed in relation to CRC development risk and patient survival. Considering a strict correction for multiple tests, we did not observe any significant association between SNPs and CRC risk. The rs3819720 polymorphism in the ABCB3/TAP2 gene was statistically significantly associated with shorter overall survival (OS) in the codominant, and dominant models [GA vs. GG, hazard ratio (HR) = 1.48; P = 0.002; AA vs. GG, HR = 1.70; P = 0.004 and GA + AA vs. GG, HR = 1.52; P = 0.0006]. Additionally, GA carriers of the same SNP displayed worse OS after receiving 5-FU based chemotherapy. The variant allele of rs3819720 polymorphism statistically significantly affected the expression of 36 downstream genes. Screening for eQTL polymorphisms in relevant genes such as ABC transporters that can regulate the expression of several other genes may help to identify the genetic background involved in the individual response to the treatment of CRC patients.
650    _2
$a ABC transportéry $x krev $x genetika $7 D018528
650    _2
$a senioři $7 D000368
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $x metabolismus $x mortalita $7 D015179
650    _2
$a databáze genetické $7 D030541
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorouracil $x terapeutické užití $7 D005472
650    _2
$a následné studie $7 D005500
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a lokus kvantitativního znaku $7 D040641
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rosa, Fabio $u IIGM Italian Institute for Genomic Medicine, Turin, Italy
700    1_
$a Susova, Simona $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Bendova, Petra $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Levy, Miroslav $u Department of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Kral, Jan $u Institute for Clinical and Experimental Medicine, IKEM, Prague, Czech Republic
700    1_
$a Bartu, Linda $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Prague, Czech Republic
700    1_
$a Vodickova, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Hughes, David J $u Cancer Biology and Therapeutics Group, UCD Conway Institute, School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland
700    1_
$a Soucek, Pavel $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Naccarati, Alessio $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Prague, Czech Republic $u IIGM Italian Institute for Genomic Medicine, Turin, Italy
700    1_
$a Kumar, Rajiv $u Division of Molecular Genetic Epidemiology $u Division of Functional Genome Analysis, German Cancer Research Centre, Heidelberg, Germany
700    1_
$a Vodicka, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Pardini, Barbara $u IIGM Italian Institute for Genomic Medicine, Turin, Italy $u Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
773    0_
$w MED00003429 $t Mutagenesis $x 1464-3804 $g Roč. 35, č. 3 (2020), s. 273-281
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31922572 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103736 $b ABA008
999    __
$a ok $b bmc $g 1650691 $s 1132748
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 35 $c 3 $d 273-281 $e 20200711 $i 1464-3804 $m Mutagenesis $n Mutagenesis $x MED00003429
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace